Placing the right bets on innovation, building powerful teams, choosing the right technologies, forging value-creating partnerships, raising capital in stressed markets–these and all the other tasks that confront Life Sciences CEOs today are daunting in themselves, and potentially overwhelming together.

 

So, how should we lead through this intensifying complexity?

 

That was the topic of the Vanguard Forum for Life Sciences CEOs on Tuesday, November 14th in Boston.

 

Chairs Fred Hassan (Warburg-Pincus), Tal Zaks (OrbiMed), and fellow co-chair Corinne Le Goff (IMUNON) were catalysts for the Forum’s conversations among an intimate group of top leaders.  

 

No PowerPoint, no podium, no presentations.  

 

Instead, the sessions generated actionable insights on what will matter most to high performance in 2024–from allocating R&D investments, to putting the right talent in the right jobs, to the continuing challenges of hybrid working.  And, above all, how to prioritize among priorities, and build the bandwidth to master the complexity.